KRAS and malignant colon neoplasm: In colon cancer, a multi-institutional diagnostic trial on percentage tumor estimates for KRAS evaluation by Viray et al, again showed considerable variation from pathologist to pathologist and similarly suggested that this could have a significant impact on molecular testing for patient stratification and therapy in colorectal cancer [6].